Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Th.

Business Wire • Feb 12, 2026

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatmen.

Business Wire • Jan 27, 2026

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025. The grants, in the form of Restricted Stock Units (RSUs), totaled.

Business Wire • Jan 21, 2026

Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade

Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earlier guidance cuts. CHOPIN trial results expand HEPZATO's potential beyond liver therapies, supporting a broader market opportunity.

Seeking Alpha • Jan 13, 2026

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025. Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $20.7 million and.

Business Wire • Jan 9, 2026

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication, titled “Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma” was published in the Journal of Cancer.

Business Wire • Dec 31, 2025

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany. The study, titled “Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uve.

Business Wire • Dec 3, 2025

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date. “The share repurcha.

Business Wire • Nov 20, 2025

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion,” was published in the Journal of Vascular and Interv.

Business Wire • Nov 18, 2025

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled “Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021,” was published in the In.

Business Wire • Nov 13, 2025